Search - tctmd.com

Displaying 1 - 14 of 14

Sort: Relevancy | Date

News Daily News

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

Todd Neale

October 02, 2025

News Daily News

AHA Statement Outlines Cardiac Contributions to Brain Health

L.A. McKeown

October 11, 2024

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

L.A. McKeown

August 21, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

Michael O'Riordan

June 23, 2023

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

News Daily News

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Michael O'Riordan

January 02, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2017

Shelley Wood

July 03, 2017

Advertisement

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

AHA Statement Outlines Cardiac Contributions to Brain Health

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Global Numbers Paint Grim Picture of GDMT Uptake, Costs, and HF Outcomes

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Ten Principles for Successful Treatment of HF With Reduced EF: New ACC Decision Pathway

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular Stories for June 2017

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content